| What is RSS feed? | About Us |
 |
 Search Score: 4/10
Source: urbanlegends.about.com --- 27 days ago
Email flier purporting to originate from U.S. government budget analysts blames inflated prescription Drug prices on price gouging by pharmacies ... Source: www.medscape.com --- 36 days ago
Abbott Laboratories has agreed to pay between $10 million and $27.5 million to settle a lawsuit contending it improperly raised the price of its HIV Drug Norvir by 400 percent. Reuters Health Information ... Source: www.topix.com --- 37 days ago
A diverse group of representatives from over 50 Mexican non-governmental agencies committed to improving the affordability of, and access to AIDS drugs in Mexico met with Mexican President Felipe Calderon in ... ... Source: www.topix.com --- 3 days ago
The U.S. subsidiary of French drugmaker Sanofi-Aventis spent more than $1.2 million in the second quarter to lobby on corporate tax and research tax credit issues, federal Drug Pricing and other matters, ... ... Source: online.wsj.com --- 32 days ago
Wyeth said it received additional subpoenas from the U.S. Attorney's Office in Massachusetts over Pricing practices and promotion of erosive esophagitis Drug Protonix. ...
Source: prweb.com --- 11 days ago
Medicare-PartD.com releases their RxSavings-Center to help Medicare beneficiaries and others find prescription Drug savings at their local retailers. The RxSavings-Center provides a variety of ways for people to compare discount Drug programs including, alphabetical searching by Drug name, searching by Drug category, or a combination search of Drug categories and discount Drug programs. Discount Drug information is also cross referenced with several lists of popular medications including a list of the top 100 Medicare drugs. Links for each medication provide users with more information on Drug strengths, form and quantity, as well as discount Drug program Pricing, availability and program stipulations. (PRWeb Aug 27, 2008) Read the full story at http://www.prweb.com/releases/2008/08/prweb1254074.htm ... Source: www.bizjournals.com --- 10 days ago
A U.S. District Court judge dismissed a suit Tuesday filed by New England Carpenters Health Benefits against one of the nation’s largest Drug distributors. (MCK) ... Source: www.medicalnewstoday.com --- 8 days ago
Medicare overpaid for irinotecan, a cancer Drug sold by Pfizer under the name Campostar, by $6.5 million in March because of a delay in updating its Pricing formula, according to a report released on Tuesday by the HHS Office of Inspector General, Bloomberg/Los Angeles Times reports. A generic version of the Drug was approved for sale on Feb. 20. ... Source: consumerist.com --- 37 days ago
Are you a coupon clipper? No? Lots of people like saving money, but don't really buy the sort of products that have coupons, or don't have time to waste searching and clipping. These tips are for you. 1) Don't waste money on pre-chopped food. Pre-chopped or single serving food is expensive! Want to save money? Buy a good knife and some plastic bags. 2) Pay attention to unit Pricing. Just because something is bigger or has a sticker on it that says "special value," doesn't mean it costs less per unit. If you hate doing math, use a calculator! 3) Try store brands. It might be the exact same food you're used to eating. The no name food you see in stores is often made by the exact same factories that produce the brand name stuff. For example, Walmart "Great Value" peanut butter is really just Peter Pan with a different label. Try the store brands. You might like them. 4) Compare prices in different areas of the store. Deli meats, cheese and olives may be a better deal than similar products in other areas of the store — or they might not. It pays to walk around and compare, says Consumer Reports. 5) Try other stores. The grocery store isn't always the cheapest place to buy food. Sometimes Drug stores have good deals on things like milk, and liquor is cheaper at warehouse stores. Discount stores like Aldi can have great deals . Farmer's markets are fun and often inexpensive. Be careful not to blow your budget by driving all over the pla ... Source: www.earthtimes.org --- 33 days ago
NEW YORK (Reuters) - U.S. prosecutors have sent subpoenas to Wyeth seeking information related to the drugmaker's promotion and Pricing of its ulcer Drug Protonix. ... Source: www.fiercepharma.com --- 22 hours ago
Times are tough all over. That's no news in the Drug biz, which has been fighting familiar battles --generic competition, Pricing pressure, et al--for a couple of years now. But they may be about to get tougher, thanks to the troubled economy. In fact, Walgreen CEO Jeffrey Rein says this is the tightest market for prescription drugs in his 27-year career. Conventional wisdom has always pegged pharma as a defensive play, given that folks have to take their meds whether they're feeling flush or not. But that reasoning doesn't necessarily hold true for certain drugs, such as cholesterol meds and blood pressure pills; patients sometimes choose to skip a few to stretch out the time between refills. In July, a poll by the National Association of Insurance Commissioners found that 11 percent of Americans had cut back on their dosages to make meds last longer, Rein said. Walgreen is hurting from this tightening up, and Rein says the trend is accelerating across the drugstore industry. Can it be long before that pain is felt by drugmakers, too? - read the article in the Wall Street Journal - see the WSJ Health Blog post Related Articles: Wanted: Rugged pharmas for tough trip Economy catches up with biotech investing Venture funds hit the brakes on biotech investing BMS to sell off company jets Venture funding slides as IPOs go into deep freeze ... Source: www.news-medical.net --- 9 days ago
Medicare overpaid for irinotecan, a cancer Drug sold by Pfizer under the name Campostar, by $6.5 million in March because of a delay in updating its Pricing formula, according to a report released on Tuesday by the HHS Office of Inspector General, Bloomberg/Los Angeles Times reports. ... Source: www.thedeal.com --- 3 days ago
As they say when it comes to retail, it is all about location, so it should come as no surprise that two retailers involved in deals are vying over the Pricing of their real estate. The first is bankrupt retailer Mervyn's LLC, which is suing three private equity firms, Cerberus Capital Management LP, Sun Capital Partners Inc. and and Lubert-Adler, as well as former parent Target Corp., for stripping down the value of its real estate due to what it alleges as a fraudulent deal. The lawsuit alleges that when Target sold Mervyn's to the PE firms for $1.26 billion in 2004 Mervyn's real estate assets were separated from its retail operations into a new entity, which in turn raised rents. Mervyn's is claiming the real estate deal drove them into bankruptcy. Separating real estate and retail operations is a pretty common move among private equity deals for tax purposes and also because PE firms then can lease some locations to other retailers. As The Wall Street Journal points out, Eddie Lampert made his fortune dolling out Kmart's real estate, and Kohlberg Kravis Roberts & Co., Bain Capital LLC and Vornado Realty Trust made similar moves when they acquired Toys 'R' Us Inc. However, the issue is not exclusive to PE retail deals. CVS Caremark Corp.'s $2.9 billion acquisition of Longs Drug Store Corp. may be facing a similar circumstance. Some of Longs' shareholders, such as activist investor CtW Investment Group, claim that CVS may have g ... Source: dealbreaker.com --- 3 days ago
We've been scolded by some of our readers for our coverage of Sarah Palin. This morning we turned to a "Washington insider" to find out about her economic outlook, largely because she didn't seem to say much about economic policy in her speech and her short tenure as governor of Alaska didn't give her much of a chance to articulate a policy. Some readers point out that we might have overlooked the gushing black elephant in the room: oil policy. Former supply-side economics, tax-cutter guru Larry Kudlow gives voice to this idea in the new York Sun today. "The no. 1 economic issue this election is gasoline prices at the pump," he writes. "And Governor Palin has the energy answer: Our abundant country can produce more energy at lower cost if government gets out of the way." There is a body of thought--increasingly popular among Republicans apparently--that holds that energy policy is the key to economic growth and financial health. Everything from home prices (pricey gas makes suburban life more expensive) to Drug prices (the cost of chemicals) to food has an energy Pricing angle. "Energy prices are the extreme marginal tax rates for the twenty-first century," a 'drill, baby, drill' Republican told us. Palin Is Our Energy Answer [New York Sun] ... Source: www.fiercepharma.com --- 34 days ago
Merck is garnering some goodwill in the AIDS community with price-freezes and discounts on its HIV-fighting drugs. First, Merck agreed to keep the new, novel med Isentress at its launch price until 2010 for state-run AIDS Drug Assistance Programs. The freeze comes after pressure from the activist group Fair Pricing Coalition, which had been lobbying Merck to launch Istentress at a "price that offers a reasonable profit" without taxing the pocketbooks of patients and payers. By keeping the price at its current $9,900 a year, Merck got a thumbs up from the group, which said, "This is a tribute to the value of having open, ongoing discussions with Drug companies. Other drugmakers have frozen their AIDS med prices, too, including Gilead Sciences and Boehringer Ingelheim. Meanwhile, Merck agreed to discount Istentress and another anti-HIV med, Stocrin, by up to 40 percent for patients in Mexico. That arrangement was announced by Mexican Health Secretary Jose Angel Cordova at the big AIDS summit now taking place in Mexico City. - check out the FPC's press release - read the post at Pharmalot Related Articles: Isentress - 2007 FDA approvals FDA approves Isentress FDA panel endorses Merck's new AIDS Drug ... Source: www.fiercepharma.com --- 34 days ago
GlaxoSmithKline is doing some fancy number-crunching in an attempt to get the U.K. to cover its cancer med Tyverb (sold as Tykerb in the U.S.). According to the Financial Times , GSK is working on a pioneering deal that would cap the cost of Tyverb--no matter how many patients sign on to use it. You'll recall that the Drug got E.U. approval for use in late-stage breast cancer, but the National Institute for Health and Clinical Excellence--which decides which meds the U.K.'s National Health Service will pay for--rejected it as too costly. So GSK has gone back to the drawing board, trying to combat the "too expensive" label with a fixed-price deal. The company would set a minimum price to cover several thousand patients, which it estimates to represent about 70 percent of those in the U.K. who might turn to Tyverb after failing on other cancer treatments. If more patients used it, the price would stay the same. Innovative Pricing methods are growing increasingly popular as drugmakers find governments less willing to pay for expensive meds. For instance, the NHS already made a deal with Johnson & Johnson to pay for the blood cancer Drug Velcade only when patients respond to it. - read the FT story Related Articles: More NICE debate over cancer meds U.K. Drug deal cuts prices 5% GSK faces Tyverb setback over safety Tykerb - 2007 FDA approvals ... Source: pharmalicensing.com --- 29 days ago
Interim Project Businees Manager required to deal with the task of investigating and developing a business plan for our client ,who is investigating the feasibility of marketing and distributing a product already approved in some other European countries.Key issues and areas that need addressing include:Assessing principal company - can our client do business successfully with them, continuity of supply, & supportEstablishing reimbursement strategy and Pricing for the respective product rangesFinancial viability i.e establishing COGS with principal, profit margins and year 1 operating costsCompetitive strategyBrand positioningFind out the best way of distributing the range in the UKPotential customer feedback. Establish likely uptake and potentials.The opportunity is for an experienced Business/Marketing/Business Development Manager to take on this assignment and complete the feasibility analysis and business planning already started.The successful candidate will have an excellent understanding and knowledge of the UK market, be an experienced Business/Marketing/Business Development Manager, have knowledge of the UK Drug tariff reimbursement process and have financial business planning skills.The position will require an intensive period of work for 1 month and needs a candidate who can completely commit him/herself to this task for that period. An immediate start is required for this position. Knowledge of dermatology and dressin ... Source: www.fiercehealthcare.com --- 10 days ago
Medicare overpaid by millions for a cancer Drug sold by Pfizer earlier this year because there was a delay in the agency updating its Pricing formula, according to a new report from the HHS Office of the Inspector General. While a generic version of the Drug, branded as Campostar, went on the market on February 20, it took Medicare two months to integrate new generic Pricing into the agency's payment system. This meant that in March, Medicare was paying $126 per dose of the generic, irinotecan, rather than the average generic price of $41. The OIG's report suggested that Medicare come up with a way to address Pricing changes resulting from the release of new generics far more quickly. To learn more about the investigation: - read this Kaiser Daily Health Policy Report piece - read this HHS OIG report (.pdf) Related Articles: HHS: Medicare pharmacy pay lower than Medicaid House passes Medicare Drug negotiation bill ... Source: www.fiercepharma.com --- 9 days ago
Answering critics of its Pricing policies, Amgen is discontinuing rebates and discounts designed to boost sales of its anemia drugs. Some said the deals induced doctors to overuse Aranesp--the anemia Drug targeted at cancer patients--at a time when questions had arisen about the drugs' safety , especially at higher doses. Oncologists will still get some up-front discounts, but they won't get rebates for Aranesp use. Nor will doctors get discounts on two other meds, Neulasta and Neupogen, based on their use of Aranesp. As you know, some studies have suggested that Aranesp and its sister Drug Procrit, sold by Johnson & Johnson, could cause cancer to grow, hasten patients' deaths and cause heart problems. Amgen has said that its discounts and rebates haven't prompted overuse of Aranesp. The company said the Pricing changes are a move to "clear up those possible misperceptions." - read the New York Times story Related Articles: Amgen CEO: "I felt real economic pain" Amgen forecast darkens as FDA review looms Epogen/Aranesp - Top 10 Warnings and Recalls Amgen in crisis? Not us, says CEO Sharer Amgen touts new Aranesp studies Amgen - Big Biotech's Stock Report ... Find more results for Drug Pricing on RSSMicro.com |
Copyright © 2008 RSSMicro.com
![This Week We Were Rage-O-Holics And Our Drug Of Choice Was Palin [The Week That Was]](http://jezebel.com/assets/images/jezebel/2008/09/sadbear111607.jpg)
For the better part of the last decade, the major record labels have been trying to convince the artists on their rosters to make their music available in multiple digital formats and from numerous online outlets. The conventional wisdom is that you have to chase customers wherever you can find them (unless, of course, they're on Limewire .) So Warner Music Group raised eyebrows last month when it yanked a promising downloadable single and album from new U.K. chanteuse Estelle off iTunes in a bid to ... boost sales? The move certainly helped two obscure cover bands, which quickly filled the void on iTunes with their own versions of Estelle's "American Boy." (Shopping tip: Accept no substitutes.) But whether it helped Estelle is an open question, as Glenn at Coolfer observes . Searching for a glimpse into the record company's rationale, I called Frank Luby, a co-author of "Manage for Profit, Not for Market Share: A Guide to Greater Profits in Highly Contested Markets." (I should have asked him about newspapers while I had him on the phone. D'ohhhh!) Luby is a partner at Simon-Kucher & Partners , Pricing and marketing consultants who work with Drug companies, automakers, consumer products manufacturers and the occasional entertainment firm, including WMG. I asked him whether he thought pulling a popular single off iTunes led to more albums being sold. His answer: There's not enough data to know. The essential problem, Luby said, is ...